Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
WST Stock Forecast 2025-2026
$208.95
Current Price
$15.48B
Market Cap
Buy 12
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to WST Price Targets
+55.5%
To High Target of $325.00
+34.0%
To Median Target of $280.00
+17.3%
To Low Target of $245.00
WST Price Momentum
-0.8%
1 Week Change
-2.9%
1 Month Change
-37.5%
1 Year Change
-36.2%
Year-to-Date Change
-40.7%
From 52W High of $352.33
+11.5%
From 52W Low of $187.43
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching West Pharmaceutical (WST) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on WST and similar high-potential opportunities.
Latest WST Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, WST has a bullish consensus with a median price target of $280.00 (ranging from $245.00 to $325.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $208.95, the median forecast implies a 34.0% upside. This outlook is supported by 12 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Paul Knight at Keybanc, projecting a 55.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
WST Analyst Ratings
12
Buy
1
Hold
0
Sell
WST Price Target Range
Low
$245.00
Average
$280.00
High
$325.00
Current: $208.95
Latest WST Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for WST.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 18, 2025 | Evercore ISI Group | Daniel Markowitz | Outperform | Initiates | $275.00 |
| Feb 14, 2025 | Keybanc | Paul Knight | Overweight | Maintains | $325.00 |
| Jan 8, 2025 | Citigroup | Thomas Palmer | Buy | Initiates | $400.00 |
| Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $355.00 |
| Dec 13, 2024 | Wolfe Research | Doug Schenkel | Peer Perform | Initiates | $0.00 |
| Dec 12, 2024 | UBS | John Sourbeer | Buy | Upgrade | $390.00 |
| Feb 16, 2024 | UBS | John Sourbeer | Neutral | Maintains | $375.00 |
| Feb 13, 2024 | Keybanc | Paul Knight | Overweight | Maintains | $470.00 |
| Feb 7, 2024 | Jefferies | David Windley | Buy | Upgrade | $536.00 |
| Oct 27, 2023 | Stephens & Co. | Jacob Johnson | Overweight | Maintains | $390.00 |
| Aug 30, 2023 | Keybanc | Paul Knight | Overweight | Maintains | $440.00 |
| Aug 21, 2023 | Keybanc | Overweight | Maintains | $0.00 | |
| Jul 28, 2023 | Keybanc | Overweight | Maintains | $0.00 | |
| Jul 17, 2023 | Stephens & Co. | Overweight | Maintains | $0.00 | |
| Jun 16, 2023 | B of A Securities | Derik De Bruin | Buy | Upgrade | $405.00 |
| Apr 11, 2023 | Stephens & Co. | Jacob Johnson | Overweight | Upgrade | $400.00 |
| Feb 17, 2023 | Keybanc | Paul Knight | Overweight | Maintains | $375.00 |
| Dec 14, 2022 | Deutsche Bank | Justin Bowers | Hold | Initiates | $250.00 |
| Dec 2, 2022 | Keybanc | Paul Knight | Overweight | Maintains | $315.00 |
| Nov 30, 2022 | UBS | John Sourbeer | Neutral | Initiates | $250.00 |
West Pharmaceutical Services Inc. (WST) Competitors
The following stocks are similar to West Pharmaceutical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
WST
West Pharmaceutical
mkt cap
15.14B
West Pharmaceutical Services Inc. (WST) Financial Data
West Pharmaceutical Services Inc. has a market capitalization of $15.48B with a P/E ratio of 33.9x. The company generates $2.90B in trailing twelve-month revenue with a 16.1% profit margin.
Revenue growth is +0.4% quarter-over-quarter, while maintaining an operating margin of +18.4% and return on equity of +17.4%.
Valuation Metrics
Market Cap
$15.48B
Enterprise Value
$15.51B
P/E Ratio
33.9x
PEG Ratio
28.6x
Price/Sales
5.3x
Growth & Margins
Revenue Growth (YoY)
+0.4%
Gross Margin
+33.2%
Operating Margin
+18.4%
Net Margin
+16.1%
EPS Growth
-22.1%
Financial Health
Cash/Price Ratio
+2.7%
Current Ratio
2.8x
Debt/Equity
11.5x
ROE
+17.4%
ROA
+10.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
West Pharmaceutical Services Inc. (WST) Business Model
About West Pharmaceutical Services Inc.
What They Do
Provides solutions for injectable drug administration.
Business Model
The company designs and manufactures packaging and delivery systems for pharmaceuticals, biologics, and vaccines, generating revenue through sales of their products such as stoppers, seals, containers, and pre-fillable syringe systems. By catering to a diverse range of healthcare and pharmaceutical clients, West Pharmaceutical Services secures ongoing partnerships with leading pharmaceutical companies, ensuring a steady demand for its innovative solutions.
Additional Information
West Pharmaceutical Services plays a crucial role in enhancing drug safety and efficacy in the healthcare sector. Its commitment to quality and innovation is vital for the development and distribution of injectable therapies across various therapeutic categories, positively impacting patient care and treatment outcomes.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
10,600
CEO
Mr. Eric M. Green
Country
United States
IPO Year
1988
Website
www.westpharma.comWest Pharmaceutical Services Inc. (WST) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
West Pharmaceutical (WST) Upgraded to Buy: Here's What You Should Know
West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
May 19, 2025
By Zacks Equity Research
Tale of the Tape
Does West Pharmaceutical (WST) Have the Potential to Rally 31.09% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 31.1% in West Pharmaceutical (WST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
May 19, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
A class action lawsuit has been filed against West Pharmaceutical Services, Inc. (NYSE: WST) and its officers, as announced by law firm Bronstein, Gewirtz & Grossman, LLC.
Why It Matters
The class action lawsuit against West Pharmaceutical Services may lead to financial liabilities, regulatory scrutiny, and potential stock volatility, impacting investor sentiment and share value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
West Pharmaceutical Services, Inc. (NYSE: WST) investors who experienced losses may explore recovery options under federal securities laws. More details can be found via the provided link.
Why It Matters
Legal actions like this can indicate potential financial instability or mismanagement within West Pharmaceutical Services, potentially impacting stock value and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Investors in West Pharmaceutical Services, Inc. (NYSE: WST) who experienced losses can explore potential recovery options under federal securities laws. More information is available via the provided link.
Why It Matters
Potential lawsuits regarding West Pharmaceutical Services could indicate financial instability or mismanagement, impacting stock performance and investor confidence.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against West Pharmaceutical Services, Inc. (NYSE:WST). Investors can contact Pomerantz LLP for more information.
Why It Matters
The class action lawsuit against West Pharmaceutical Services may indicate potential legal and financial risks, impacting stock performance and investor sentiment.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Investors in West Pharmaceutical Services, Inc. (NYSE: WST) who experienced losses may explore potential recovery options under federal securities laws. More information is available via the provided link.
Why It Matters
The news indicates potential legal action against West Pharmaceutical Services, which could impact stock performance and investor sentiment, leading to volatility in the company's shares.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against West Pharmaceutical Services, Inc. (NYSE: WST) for alleged federal securities law violations affecting investors between February 16, 2023, and February 12, 2025.
Why It Matters
A class action lawsuit against West Pharmaceutical could lead to financial liabilities and affect stock price, signaling potential risks for current and future investors.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About WST Stock
What is West Pharmaceutical Services Inc.'s (WST) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, West Pharmaceutical Services Inc. (WST) has a median price target of $280.00. The highest price target is $325.00 and the lowest is $245.00.
Is WST stock a good investment in 2025?
According to current analyst ratings, WST has 12 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $208.95. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for WST stock?
Wall Street analysts predict WST stock could reach $280.00 in the next 12 months. This represents a 34.0% increase from the current price of $208.95. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is West Pharmaceutical Services Inc.'s business model?
The company designs and manufactures packaging and delivery systems for pharmaceuticals, biologics, and vaccines, generating revenue through sales of their products such as stoppers, seals, containers, and pre-fillable syringe systems. By catering to a diverse range of healthcare and pharmaceutical clients, West Pharmaceutical Services secures ongoing partnerships with leading pharmaceutical companies, ensuring a steady demand for its innovative solutions.
What is the highest forecasted price for WST West Pharmaceutical Services Inc.?
The highest price target for WST is $325.00 from Paul Knight at Keybanc, which represents a 55.5% increase from the current price of $208.95.
What is the lowest forecasted price for WST West Pharmaceutical Services Inc.?
The lowest price target for WST is $245.00 from at , which represents a 17.3% increase from the current price of $208.95.
What is the overall WST consensus from analysts for West Pharmaceutical Services Inc.?
The overall analyst consensus for WST is bullish. Out of 11 Wall Street analysts, 12 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $280.00.
How accurate are WST stock price projections?
Stock price projections, including those for West Pharmaceutical Services Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 22, 2025 7:23 AM UTC